Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| ciliated cell | 6 studies | 30% ± 8% | |
| endothelial cell | 4 studies | 17% ± 1% | |
| epithelial cell | 4 studies | 34% ± 11% | |
| enterocyte | 3 studies | 22% ± 5% |
Insufficient scRNA-seq data for expression of GBP3 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| bladder | 100% | 1535.90 | 21 / 21 | 88% | 36.28 | 444 / 504 |
| breast | 99% | 1433.41 | 456 / 459 | 88% | 39.14 | 989 / 1118 |
| thymus | 100% | 1529.40 | 650 / 653 | 87% | 47.02 | 526 / 605 |
| esophagus | 98% | 1034.74 | 1415 / 1445 | 88% | 34.60 | 161 / 183 |
| lung | 100% | 3076.75 | 578 / 578 | 86% | 32.59 | 988 / 1155 |
| intestine | 99% | 2182.33 | 953 / 966 | 87% | 40.13 | 456 / 527 |
| stomach | 95% | 1131.21 | 342 / 359 | 90% | 43.15 | 257 / 286 |
| kidney | 100% | 2049.29 | 89 / 89 | 85% | 40.71 | 762 / 901 |
| uterus | 100% | 1376.34 | 170 / 170 | 84% | 32.84 | 385 / 459 |
| ovary | 100% | 1255.59 | 180 / 180 | 78% | 23.94 | 337 / 430 |
| prostate | 100% | 1978.35 | 245 / 245 | 74% | 21.36 | 370 / 502 |
| pancreas | 68% | 373.08 | 223 / 328 | 90% | 48.82 | 160 / 178 |
| liver | 89% | 576.74 | 202 / 226 | 63% | 15.04 | 257 / 406 |
| skin | 92% | 908.55 | 1668 / 1809 | 60% | 15.64 | 283 / 472 |
| adrenal gland | 99% | 1768.14 | 255 / 258 | 27% | 5.17 | 62 / 230 |
| brain | 53% | 317.83 | 1413 / 2642 | 64% | 21.16 | 451 / 705 |
| spleen | 100% | 1956.03 | 241 / 241 | 0% | 0 | 0 / 0 |
| adipose | 99% | 1460.03 | 1191 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 99% | 1436.36 | 1316 / 1335 | 0% | 0 | 0 / 0 |
| heart | 89% | 609.09 | 769 / 861 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 78% | 21.45 | 35 / 45 |
| lymph node | 0% | 0 | 0 / 0 | 72% | 14.96 | 21 / 29 |
| peripheral blood | 68% | 509.33 | 635 / 929 | 0% | 0 | 0 / 0 |
| muscle | 17% | 59.75 | 138 / 803 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 9% | 1.54 | 7 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0071222 | Biological process | cellular response to lipopolysaccharide |
| GO_0051715 | Biological process | cytolysis in another organism |
| GO_0140639 | Biological process | positive regulation of pyroptotic inflammatory response |
| GO_0051607 | Biological process | defense response to virus |
| GO_0071356 | Biological process | cellular response to tumor necrosis factor |
| GO_0071347 | Biological process | cellular response to interleukin-1 |
| GO_0071346 | Biological process | cellular response to type II interferon |
| GO_0042742 | Biological process | defense response to bacterium |
| GO_0000139 | Cellular component | Golgi membrane |
| GO_0005829 | Cellular component | cytosol |
| GO_0031410 | Cellular component | cytoplasmic vesicle |
| GO_0048471 | Cellular component | perinuclear region of cytoplasm |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0005525 | Molecular function | GTP binding |
| GO_0042803 | Molecular function | protein homodimerization activity |
| GO_0042802 | Molecular function | identical protein binding |
| GO_0005515 | Molecular function | protein binding |
| GO_0003924 | Molecular function | GTPase activity |
| Gene name | GBP3 |
| Protein name | Guanylate-binding protein 3 (EC 3.6.5.-) (GTP-binding protein 3) (GBP-3) (Guanine nucleotide-binding protein 3) Guanylate binding protein 3 |
| Synonyms | hCG_2039462 |
| Description | FUNCTION: Interferon (IFN)-inducible GTPase that plays important roles in innate immunity against a diverse range of bacterial, viral and protozoan pathogens . Hydrolyzes GTP very efficiently; GDP rather than GMP is the major reaction product (By similarity). Following infection, recruited to the pathogen-containing vacuoles or vacuole-escaped bacteria and acts as a positive regulator of inflammasome assembly by promoting the release of inflammasome ligands from bacteria (By similarity). Acts by promoting lysis of pathogen-containing vacuoles, releasing pathogens into the cytosol (By similarity). Following pathogen release in the cytosol, promotes recruitment of proteins that mediate bacterial cytolysis: this liberates ligands that are detected by inflammasomes, such as lipopolysaccharide (LPS) that activates the non-canonical CASP4/CASP11 inflammasome or double-stranded DNA (dsDNA) that activates the AIM2 inflammasome (By similarity). Exhibits antiviral activity against influenza virus . .; FUNCTION: [Isoform 2]: Shows the most prominent antiviral activity in epithelial cells. . |
| Accessions | H3BPH2 ENST00000445969.1 F6X827 ENST00000568006.1 H3BP53 ENST00000461384.6 Q5T8M0 ENST00000564665.1 ENST00000493594.6 ENST00000489444.6 H3BNS1 H3BRX6 Q9H0R5 ENST00000235878.5 F6SPX6 ENST00000370481.9 [Q9H0R5-1] |